Research graph
References from Phytochemical–drug combinations in osteosarcoma: Mechanistic vulnerabilities, evidence quality and translational challenges. Local targets link to admitted publications; unresolved targets remain external evidence.
Synergistic composite engineering: bridging immunomodulaftion, bone regeneration and precision therapy in osteosarcoma management
10.1016/j.nantod.2025.102952 · 2026 · External reference
Modern trends of using innovative nanoparticle approaches for immune-based osteosarcoma therapy
10.1016/j.intimp.2025.115953 · 2026 · External reference
Systemic strategies for osteosarcoma: advances and future directions
10.1007/s12672-025-02208-9 · 2025 · External reference
UK guidelines for the management of bone sarcomas
10.1038/s41416-024-02868-4 · 2025 · External reference
Risk factors for pulmonary metastases in osteosarcoma: a systematic review and meta-analysis
10.1186/s12885-026-15802-z · 2026 · External reference
Prognostic nomogram for overall survival in pediatric osteosarcoma with pulmonary metastases: a SEER database analysis
2025 · External reference
From bone homeostasis to skeletal metastasis and osteosarcoma: insights into osteoclast and osteoblast roles in bone remodelling and cancer
2026 · External reference
Osteosarcoma and metastasis
10.3389/fonc.2021.780264 · 2021 · External reference
Recurrent metastatic high-grade osteosarcoma: disease stabilization and successful pregnancy outcome following aggressive multimodality treatment
10.4103/ijmpo.ijmpo_83_17 · 2018 · External reference
Advances in osteosarcoma research: pathogenesis and emerging therapeutic strategies
10.1016/j.critrevonc.2026.105252 · 2026 · External reference
Osteosarcoma: current concepts and evolutions in management principles, journal of
2023 · External reference
Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: a meta-analysis and clinical observation
10.1097/md.0000000000015582 · 2019 · External reference
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
10.1016/s1470-2045(16)30214-5 · 2016 · External reference
Completion of perioperative chemotherapy and tumor regression grade as independent predictors of one-year survival after total gastrectomy for gastric cancer: a retrospective cohort study
10.1186/s12957-026-04364-w · 2026 · External reference
Pathological complete response after neoadjuvant chemotherapy in breast cancer: a literature overview
10.3390/cancers18111718 · 2026 · External reference
Long-term benefit from high-dose ifosfamide in sarcoma depends on sustained prior control and timely intervention: a machine learning analysis
10.1007/s00432-025-06410-8 · 2026 · External reference
High dose ifosfamide in relapsed and unresectable high-grade osteosarcoma patients: a retrospective series
10.3390/cells9112389 · 2020 · External reference
Battling Chemoresistance in cancer: root causes and strategies to uproot them
10.3390/ijms22179451 · 2021 · External reference
Mechanisms and advances of drug resistance in colorectal cancer: a systematic overview of multi-layered regulatory networks
10.1016/j.tranon.2026.102886 · 2026 · External reference
Advancements in osteosarcoma therapy: overcoming chemotherapy resistance and exploring novel pharmacological strategies
10.3390/ph18040520 · 2025 · External reference
Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance
10.1016/j.gendis.2022.11.025 · 2024 · External reference
Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics
10.1016/j.gendis.2022.02.007 · 2023 · External reference
Emerging therapeutic strategies for triple-negative breast cancer using ruthenium, iridium, and rhenium complexes
10.1039/d6dt01362g · 2026 · External reference
Cisplatin for cancer therapy and overcoming chemoresistance
10.1016/j.heliyon.2022.e10608 · 2022 · External reference
Advances in understanding cisplatin-induced toxicity: molecular mechanisms and protective strategies
10.1016/j.ejps.2024.106939 · 2024 · External reference
Cisplatin resistance in oral squamous cell carcinoma: mechanisms, reversal strategies, and emerging technologies
2026 · External reference
Colorectal cancer at the crossroads: the good, the bad, and the future of platinum-based drugs
10.1021/acs.chemrev.5c00041 · 2025 · External reference
Doxorubicin-an agent with multiple mechanisms of anticancer activity
10.3390/cells12040659 · 2023 · External reference
Different mechanisms in doxorubicin-induced cardiomyopathy: impact of BRCA1 and BRCA2 mutations
10.3390/hearts5010005 · 2024 · External reference
Resistance to doxorubicin therapy in breast cancer cells could be attenuated by ligustilide: impact on autophagy and LncRNA H19
10.1186/s12906-026-05397-0 · 2026 · External reference
Targeting activated pathways in doxorubicin-resistant TNBC alters signaling, survival and EMT: a double-edged sword
10.3390/ijms27062792 · 2026 · External reference
Methotrexate an old drug with new tricks
10.3390/ijms20205023 · 2019 · External reference
A narrative review on diagnosis and treatment of ifosfamide-induced encephalopathy, the perspective of a EURACAN reference center for sarcomas
2025 · External reference
The heterogeneity and drug resistance of malignant cells and intercellular communication of microenvironment in osteosarcoma: based on single-cell analysis
10.1002/ctd2.202 · 2023 · External reference
Molecular mechanisms of chemoresistance in osteosarcoma (review)
10.3892/ol.2014.1935 · 2014 · External reference
NF-κB in biology and targeted therapy: new insights and translational implications
10.1038/s41392-024-01757-9 · 2024 · External reference
Key signal transduction pathways and crosstalk in cancer: biological and therapeutic opportunities
10.1016/j.tranon.2022.101510 · 2022 · External reference
Metabolic–immune crosstalk in osteosarcoma: mechanisms and therapeutic opportunities
2026 · External reference
Tumor microenvironment in osteosarcoma: from cellular mechanism to clinical therapy
10.1016/j.gendis.2025.101569 · 2025 · External reference
Targeting redox homeostasis in cancer: inhibitors of reactive oxygen species regulating cellular signalling pathways and their therapeutic implications
10.1016/j.critrevonc.2026.105204 · 2026 · External reference
Drug-induced oxidative stress in cancer treatments: angel or devil?
10.1016/j.redox.2023.102754 · 2023 · External reference
Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications
10.1038/s41392-026-02583-x · 2026 · External reference
The significance of antioxidants and their cellular mechanisms that defend against oxidative stress: a review
10.1016/j.nexres.2026.101908 · 2026 · External reference
Nonapoptotic cell death pathways
2022 · External reference
The therapeutic potential of targeting regulated non-apoptotic cell death
10.1038/s41573-023-00749-8 · 2023 · External reference
Phytochemicals as promising lead compounds for drug discovery: a comprehensive review of mechanisms and pharmacological potentials
10.1016/j.lddd.2026.100363 · 2026 · External reference
Phytochemicals from natural sources classification physiological roles and health benefits
10.1007/s44371-026-00781-8 · 2026 · External reference
Flavonoids as promising molecules in the cancer therapy: an insight
10.1016/j.crphar.2023.100167 · 2024 · External reference
Anticancer properties of phenolic acids and cell death signaling pathways: a 20-year bibliometric analysis (2003−2023)
10.1016/j.fbio.2024.105741 · 2025 · External reference
Therapeutic role of alkaloids and alkaloid derivatives in Cancer management
10.3390/molecules28145578 · 2023 · External reference
Therapeutic potential of certain Terpenoids as anticancer agents: a scoping review
10.3390/cancers14051100 · 2022 · External reference
Multi-target saponins in cancer therapy: direct binding mechanisms and lipid-based nanoparticles as a synergistic solution
10.1016/j.cej.2025.169109 · 2025 · External reference
Quinone scaffolds as potential therapeutic anticancer agents: chemistry, mechanism of actions, structure-activity relationships and future perspectives
10.1016/j.rechem.2024.101432 · 2024 · External reference
Baicalein mediates the anti-tumor activity in osteosarcoma through lncRNA-NEF driven Wnt/beta-catenin signaling regulatory axis
10.1016/j.jot.2021.12.001 · 2022 · External reference
Baicalin induces apoptosis and autophagy in human osteosarcoma cells by increasing ROS to inhibit PI3K/Akt/mTOR, ERK1/2 and beta-catenin signaling pathways
10.1016/j.jbo.2022.100415 · 2022 · External reference
Pulsatilla saponin D inhibited the growth of osteosarcoma by regulating the JNK/ATF3 signaling pathway
10.1016/j.cbi.2025.111420 · 2025 · External reference
Robinetin inhibits osteosarcoma proliferation and migration, acting via the slug/twist signaling axis
10.1016/j.ejphar.2025.178432 · 2026 · External reference
Magnoflorine inhibits the malignant phenotypes and increases cisplatin sensitivity of osteosarcoma cells via regulating miR-410-3p/HMGB1/NF-kappaB pathway
10.1016/j.lfs.2020.117967 · 2020 · External reference
Recent advances and future perspectives in multidisciplinary research on osteosarcoma
10.1007/s44178-025-00217-w · 2026 · External reference
Phytochemicals and REDOX modulation: molecular mechanisms, clinical relevance, and therapeutic perspectives
10.3390/antiox15020272 · 2026 · External reference
Oxidative stress: the role of antioxidant phytochemicals in the prevention and treatment of diseases
10.3390/ijms25063264 · 2024 · External reference
Targeting oxidative stress-mediated regulated cell death as a vulnerability in cancer
10.1016/j.redox.2025.103686 · 2025 · External reference
The role of redox homeostasis in tumor progression: implications for cancer therapy
10.1016/j.actbio.2025.07.067 · 2025 · External reference
Precision redox oncology: exploiting antioxidant dependencies and oxidative vulnerabilities in cancer
10.1016/j.chphi.2026.101054 · 2026 · External reference
Targeting metabolic redox vulnerabilities via a multi-modal MOF nanoplatform for synergistic ROS-mediated cancer therapy
10.1016/j.cej.2026.177700 · 2026 · External reference
Synergistic effects of natural compounds and conventional chemotherapeutic agents: recent insights for the development of cancer treatment strategies
10.1016/j.heliyon.2022.e09519 · 2022 · External reference
Natural bioactive molecules and chemotherapeutics synergism for enhanced cancer therapy
10.1186/s12986-026-01094-4 · 2026 · External reference
Understanding the anticancer effects of phytochemicals: from molecular docking to Anticarcinogenic signaling
10.1016/j.tjnut.2024.11.015 · 2025 · External reference
Phytochemicals as a complement to Cancer chemotherapy: pharmacological modulation of the autophagy-apoptosis pathway
2021 · External reference
Deciphering the cancer chemopreventive potential of phytochemicals: an integrative perspective on molecular targets and signaling networks
10.1186/s12935-025-04109-x · 2026 · External reference
Formononetin enhances cisplatin chemotherapy sensitivity in osteosarcoma by inducing ferroptosis and reconstructing the immune microenvironment
10.1016/j.phymed.2025.156960 · 2025 · External reference
EGCG regulated osteolytic microenvironment to enhance the antitumor effect of DOX on orthotopic osteosarcoma
10.1016/j.jff.2022.105118 · 2022 · External reference
Lycorine combined with cisplatin synergistically inhibited osteosarcoma cells growth and metastasis by suppressing Wnt/β-catenin and STAT3 signaling pathways
10.1016/j.jff.2024.106339 · 2024 · External reference
Tannic acid enhances cisplatin effect on cell proliferation and apoptosis of human osteosarcoma cell line (U2OS)
10.1007/s43440-021-00330-3 · 2022 · External reference
Pectolinarigenin acts as a potential anti-osteosarcoma agent via mediating SHP-1/JAK2/STAT3 signaling
10.1016/j.biopha.2022.113323 · 2022 · External reference
Chalcones induce apoptosis, autophagy and reduce spreading in osteosarcoma 3D models
10.1016/j.biopha.2024.117284 · 2024 · External reference
Veratramine influences the proliferation of human osteosarcoma cells through modulating the PI3K/AKT signaling cascade
2026 · External reference
Anti-osteosarcoma activity of Corynoline via Src/JNK signaling-mediated cell cycle arrest and mitochondrial apoptosis
10.1016/j.intimp.2025.114126 · 2025 · External reference
9-O-monoethyl succinate berberine effectively blocks the PI3K/AKT signaling pathway by targeting Wnt5a protein in inhibiting osteosarcoma growth
10.1016/j.phymed.2024.155430 · 2024 · External reference
Harmine exerts anticancer effects through the ROS/p38 axis to induce autophagy and apoptosis in osteosarcoma
10.1016/j.bioorg.2025.108557 · 2025 · External reference
Rosmarinic acid exerts an anticancer effect on osteosarcoma cells by inhibiting DJ-1 via regulation of the PTEN-PI3K-Akt signaling pathway
10.1016/j.phymed.2020.153186 · 2020 · External reference
Acetylshikonin induces apoptosis of human osteosarcoma U2OS cells by triggering ROS-dependent multiple signal pathways
10.1016/j.tiv.2022.105521 · 2023 · External reference
Acacetin inhibits the tumor growth of human osteosarcoma cells through regulating Wnt/β-catenin and JNK signaling pathways
10.1016/j.jff.2022.105103 · 2022 · External reference
Piperlongumine induces apoptosis and G(2)/M phase arrest in human osteosarcoma cells by regulating ROS/PI3K/Akt pathway
10.1016/j.tiv.2020.104775 · 2020 · External reference
Brusatol inhibits malignant phenotypes and lipid metabolism of osteosarcoma cells by regulating PI3K/AKT and MAPK pathways
10.1016/j.phymed.2025.156464 · 2025 · External reference
Guggulsterone suppresses osteosarcoma progression by inhibiting glycolysis through MAPK signaling pathway
10.1016/j.phymed.2025.156949 · 2025 · External reference
Piperine inhibits proliferation of human osteosarcoma cells via G2/M phase arrest and metastasis by suppressing MMP-2/−9 expression
10.1016/j.intimp.2014.11.012 · 2015 · External reference
Ziyuglycoside II suppressed the progression of osteosarcoma by coordinating estrogen-related receptor gamma and p53 signaling pathway
2025 · External reference
Reactive oxygen species signaling and oxidative stress: transcriptional regulation and evolution
2024 · External reference
Redox metabolism: ROS as specific molecular regulators of cell signaling and function
10.1016/j.molcel.2021.08.018 · 2021 · External reference
Brusatol induced ferroptosis in osteosarcoma cells by modulating the Keap1/Nrf2/SLC7A11 signaling pathway
10.1016/j.phymed.2025.156912 · 2025 · External reference
Licochalcone B targets neural cell adhesion molecule 1 to inhibit osteosarcoma progression and ferroptosis resistance via extracellular signal-regulated kinase 5 and nuclear factor kappa B pathways
2025 · External reference
Piperlongumine inhibits the progression of osteosarcoma by downregulating the SOCS3/JAK2/STAT3 pathway via miR-30d-5p
10.1016/j.lfs.2021.119501 · 2021 · External reference
Anti-tumour potential and selectivity of caffeic acid phenethyl ester in osteosarcoma cells
10.1016/j.tice.2021.101705 · 2022 · External reference
Dihydromyricetin suppresses cell metastasis in human osteosarcoma through SP-1- and NF-kappaB-modulated urokinase plasminogen activator inhibition
10.1016/j.phymed.2021.153642 · 2021 · External reference
Ziyuglycoside II, a triterpene glycoside compound in Sanguisorbae officinalis l. extract, suppresses metastasis in osteosarcoma via CBX4-mediated Wnt/beta-catenin signal pathway
10.1016/j.phymed.2024.155716 · 2024 · External reference
Antitumor effects of cannabidiol (CBD) on osteosarcoma by targeting TNF-alpha/NF-kappaB/CCL5 signaling axis
10.1016/j.phymed.2025.157066 · 2025 · External reference
Rhizoma Paridis saponins suppresses vasculogenic mimicry formation and metastasis in osteosarcoma through regulating miR-520d-3p/MIG-7 axis
10.1016/j.jphs.2022.08.005 · 2022 · External reference
Cyclovirobuxine D inhibits the growth of osteosarcoma cells through the induction of autophagy flux arrest by promoting lysosomal acidification
10.1016/j.jff.2024.106210 · 2024 · External reference
Naringenin induces ferroptosis in osteosarcoma cells through the STAT3-MGST2 signaling pathway
10.1016/j.jbo.2024.100657 · 2025 · External reference
Metastatic progression of osteosarcomas: a review of current knowledge of environmental versus oncogenic drivers
10.3390/cancers14020360 · 2022 · External reference
Mechanisms of angiogenesis in tumour
2024 · External reference
Physiological and tumor-associated angiogenesis: key factors and therapy targeting VEGF/VEGFR pathway
10.1016/j.biopha.2024.117585 · 2024 · External reference
Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
10.1186/s13046-024-02949-5 · 2024 · External reference
STAT3 axis in cancer and cancer stem cells: from oncogenesis to targeted therapies, Biochimica et Biophysica Acta (BBA) - reviews on
2025 · External reference
Curculigoside exhibits multiple therapeutic ef fi cacy to induce apoptosis and ferroptosis in osteosarcoma via modulation of ROS and tumor microenvironment
10.1016/j.tice.2025.102745 · 2025 · External reference
Ferroptosis, a distinct form of cell death, and research progress on its modulators
10.3390/ph18121785 · 2025 · External reference
Ferroptosis: emerging mechanisms, biological function, and therapeutic potential in cancer and inflammation
10.1038/s41420-024-01825-7 · 2024 · External reference
Ferroptosis: mechanisms, biology and role in disease
10.1038/s41580-020-00324-8 · 2021 · External reference
Ferroptosis: a cell death connecting oxidative stress, inflammation and cardiovascular diseases
10.1038/s41420-021-00579-w · 2021 · External reference
Brief guide to detecting ferroptosis
10.1016/j.mocell.2025.100276 · 2025 · External reference
The cell biology of ferroptosis
10.1038/s41580-024-00703-5 · 2024 · External reference
Interaction mechanisms between autophagy and ferroptosis: potential role in colorectal cancer
10.4251/wjgo.v15.i7.1135 · 2023 · External reference
R. Skouta, Eleina M. Zaitsev, Caroline E. Gleason, Darpan N. Patel, Andras J. Bauer, Alexandra M. Cantley, Wan S. Yang, B. Morrison, Brent R. Stockwell, Ferroptosis: An Iron-dependent form of nonapoptotic cell death
10.1016/j.cell.2012.03.042 · 2012 · External reference
A natural protopanaxatriol from Panax notoginseng enhances osteosarcoma sensitivity to ferroptosis via ASCL4 upregulation
10.1016/j.jff.2024.106488 · 2024 · External reference
DNA damage response and repair in osteosarcoma: defects, regulation and therapeutic implications
10.1016/j.dnarep.2021.103105 · 2021 · External reference
Evaluation of synergism in drug combinations and reference models for future orientations in oncology
10.1016/j.crphar.2022.100110 · 2022 · External reference
Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls
10.1016/j.drudis.2019.09.002 · 2019 · External reference
SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets
10.1016/j.gpb.2022.01.004 · 2022 · External reference
Bioaccessibility and bioavailability of phytochemicals: influencing factors, improvements, and evaluations
10.1016/j.foodhyd.2022.108165 · 2023 · External reference
Exploring the therapeutic potential of phytochemicals: challenges and strategies for clinical translation
10.1016/j.phymed.2025.157090 · 2025 · External reference
Far from being a simple question: the complexity between in vitro and in vivo responses from nutrients and bioactive compounds with antioxidant potential
10.1016/j.foodchem.2022.134351 · 2023 · External reference
Selection of clinically relevant drug concentrations for in vitro studies of candidates drugs for cancer repurposing: a proposal
10.1007/s12094-023-03352-w · 2024 · External reference
Estimating drug concentration–response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes
10.1177/09622802231212274 · 2023 · External reference
Exploring synergistic effects of bioactive compounds and pharmaceuticals in therapeutic applications
10.1016/j.jhip.2026.02.009 · 2026 · External reference
Pharmacokinetic interactions in synergistic herb-drug combinations
2022 · External reference
Curcumin as a modulator of drug metabolism and gene expression: implications for pharmacogenomics
10.1016/j.prerep.2025.100067 · 2025 · External reference
Phytochemicals that interfere with drug metabolism and transport, modifying plasma concentration in humans and animals
10.1177/15593258221120485 · 2022 · External reference
Phytochemicals in Cancer therapy: a structured review of mechanisms, challenges, and Progress in personalized treatment
10.1002/cbdv.202402479 · 2025 · External reference
Therapeutic resistance and combination therapy for cancer: recent developments and future directions
10.1038/s41598-025-12725-w · 2025 · External reference
Combined therapy in Cancer treatment
2025 · External reference
Role of tumor microenvironment in cancer progression and therapeutic strategy
10.1002/cam4.5698 · 2023 · External reference
Evaluation of tumor control and Normal tissue complication probabilities in patients receiving comprehensive nodal irradiation for left-sided breast Cancer
10.3390/curroncol31060241 · 2024 · External reference
Nanotechnology-enabled delivery systems to improve the bioavailability and efficacy of polyphenolic compounds
10.1016/j.prenap.2026.100532 · 2026 · External reference
Liposomes: recent progress on nanoparticles production and their usage in medicine, biomaterials
2026 · External reference
Recent advances in drug delivery systems for osteosarcoma therapy and bone regeneration
10.1038/s43246-024-00612-2 · 2024 · External reference
Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics
10.1186/s12951-023-01826-1 · 2023 · External reference
Nanocarrier-assisted phytochemical drug delivery in cancer therapy: a bibliometric analysis and integrative review of challenges, innovations, and translational potential
10.1016/j.prerep.2026.100075 · 2026 · External reference
Nanomaterials for delivery of medicinal plant extracts and phytochemicals: potential applications and future perspectives
10.1016/j.plana.2025.100161 · 2025 · External reference
3D cell culture models: drug pharmacokinetics, safety assessment, and regulatory consideration
10.1111/cts.13066 · 2021 · External reference
Advancements in 3D cell culture Systems for Personalizing Anti-Cancer Therapies
10.3389/fonc.2021.782766 · 2021 · External reference
Cancer metastasis: molecular mechanisms and therapeutic interventions
10.1186/s43556-025-00261-y · 2025 · External reference
Multiple roles of p53 in cancer development: regulation of tumor microenvironment, m6A modification and diverse cell death mechanisms
10.1016/j.jare.2024.10.026 · 2025 · External reference
Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives
10.1038/s41392-024-01885-2 · 2024 · External reference
